Nabriva Therapeutics Expands XENLETA® Presence with Exclusive Agreement with Er-Kim Pharmaceuticals
DUBLIN, Ireland and FORT WASHINGTON, Pa., July 18, 2022 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical...
Nabriva Therapeutics Expands XENLETA® Presence with Exclusive Agreement with Er-Kim Pharmaceuticals
Er-Kim Partners with Kyowa Kirin to Commercialize Palliative Care Portfolio in Eleven CEE Countries
Quoin Pharmaceuticals Extends Exclusive Distribution Agreement with Er-Kim for its Lead Asset, QRX00
Quoin Pharmaceuticals Signs Exclusive Distribution Agreement with Er-Kim for its Lead Asset, QRX003
Aeterna Zentaris & Er-Kim Announce Partnership to Commercialize Macrilen in Eight European Countries